Symbol="IMMX"
AssetType="Common Stock"
Name="Immix Biopharma Inc"
Description="Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California."
CIK="1873835"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="32899300"
EBITDA="-11567278"
PERatio="None"
PEGRatio="None"
BookValue="0.813"
DividendPerShare="0"
DividendYield="0"
EPS="-0.82"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.417"
ReturnOnEquityTTM="-0.731"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.82"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="11"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.156"
EVToRevenue="-"
EVToEBITDA="-0.0128"
Beta="None"
num_52WeekHigh="3.29"
num_52WeekLow="0.68"
num_50DayMovingAverage="2.173"
num_200DayMovingAverage="2.011"
SharesOutstanding="16286800"
DividendDate="None"
ExDividendDate="None"
symbol="IMMX"
open="2.06"
high="2.10"
low="1.88"
price="2.02"
volume="111107.00"
latest_trading_day="2023-08-25"
previous_close="2.04"
change="-0.02"
change_percent="-0.9804%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="68"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="32"
Volume_recent_avg="250643"
Change_recent_avg="0.01"
Delta_recent_avg="0.2"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.17"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="32"
Aroon_momentum_negative="68"
image_negative_thumbnail_id_1="139"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0037.jpeg"
image_negative_thumbnail_id_2="1154"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0188.jpeg"
image_neutral_thumbnail_id_1="432"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Neutral_Landscape_0019.jpeg"
image_neutral_thumbnail_id_2="526"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0073.jpeg"
image_positive_thumbnail_id_1="697"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0011.jpeg"
image_positive_thumbnail_id_2="617"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0091.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1199"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
